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Background: Antenatal screening has the capacity to detect more than 90% of Down’s syndrome pregnancies leading 
to therapeutic abortion.  Successes in recent years with such so-called ‘secondary’ prevention have not been matched 
with progress in primary prevention. Despite considerable research over many decades the principle cause of the 
disorder is unknown.   
Methods: This paper considers three potential primary prevention strategies, (1) avoiding reproduction at advanced 
maternal age, (2) pre-implantation genetic diagnosis for couples who are at high risk of Down’s syndrome, and (3) 
folic acid supplementation. The principle aetiological hypotheses are also reviewed. 
Interpretation: A strategy of completing the family before a maternal age of 30 could more than halve the birth 
prevalence of this disorder. Women with a high a priori risk should have access to pre-implantation genetic 
diagnosis, which can lead to a reasonably high pregnancy rate with an extremely low risk of a Down’s syndrome. 
The evidence suggesting an aetiological role for defective folate and methyl metabolism is not sufficient to justify an 
active preventative strategy of folic acid supplementation without performing a large clinical trial. Current 
supplementation policies designed to prevent neural tube defects may incidentally prevent Down’s syndrome, 
provided a sufficiently high dose of folic acid is used. Further progress in primary prevention is hampered by 
limited aetiological knowledge and there is an urgent need to refocus research in that direction. 
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1.  Introduction  
Aneuploidy is a common event in pregnancy 
although most affected embryos abort spontaneously 
early in the first trimester.  Those that survive into the 
second trimester also experience high late intrauterine 
mortality and increased risk of infant death.  Viability and 
clinical outcome vary according to the genotype and this 
paper will concentrate on Down’s syndrome (DS), the 
most common form of aneuploidy which is sufficiently 
viable to survive to term in relatively large numbers. 
In the absence of prenatal diagnosis and therapeutic 
abortion, the prevalence of DS in developed countries is 1-
2 per 1,000 births making it the most frequent identifiable 
cause of severe learning difficulty. In 95% of cases there is 
non-disjunction of chromosome 21, in 4% a translocation 
and 1% are mosaic [1]. 
Advanced maternal age is by far the strongest 
epidemiological variables with birth prevalence increasing 
from 0.6 to 4.1 per 1,000 between age 15 and 45 [2].  There 
is familial aggregation: having had a previous DS 
pregnancy confers a risk 4.2 per 1,000 higher risk than the 
age-specific prevalence [3].  Other risk factors are 
considerably weaker [4]. 
DNA analysis in the parents of children with non-
disjunction trisomy 21 shows that the extra chromosome 
is maternal in origin for about 90% and that certain types 
of cross-over during maternal meiosis confer a substantial 
susceptibility [5].  The parents also have an altered 
distribution of polymorphisms in the genes for 
apolipoprotein E [6], presenilin-1a [7], 5,10-methylene-
tetrahydrofolate reductase (MTHFR) and methionine 
synthase reductase (MTRR) [8-13].  The latter 
polymorphisms together with biochemical and 
epidemiological evidence suggest an association with 
impaired folate and homocystine metabolism [14]. 
In recent decades considerable attention has been 
given to the so-called ‘secondary’ prevention of DS 
through antenatal screening followed by invasive prenatal 
diagnosis and termination of affected pregnancies.  In the 
past women were selected for prenatal diagnosis on the 
basis of high risk – largely advanced maternal age or 
family history.  However, this had little impact on birth 
prevalence since most cases occur without any specific 
indication.  Moreover, the advanced age group include a 
disproportionate number who would not accept 
termination for religious reasons and many who would 
not accept the hazards of invasive prenatal diagnosis after 
an extended period of infertility.  Today the situation is 
very different.  Antenatal screening using multiple 
biochemical and ultrasound markers is routine in 
developed countries.  The best techniques are now 
capable of detecting more than 90% of affected 
pregnancies [15] and this approach appears to be 
generally acceptable to pregnant women [16].  These 
successes with so-called ‘secondary’ prevention have not 
been matched with progress in primary prevention.   
Despite considerable research over many decades the 
principle cause of DS is unclear.  Nevertheless some 
preventative strategies might be considered: avoiding late 
reproduction, pre-implantation genetic diagnosis (PGD) 
and folic acid supplementation.  To make further progress 
there is an urgent need to refocus aetiological research so 
as to build on recent findings. 
2.  Avoiding late reproduction  
A simple preventative strategy that anyone can 
undertake is to complete their family at a relatively young Int. J. Med. Sci. 2005 2  94
age.  The risk of an affected pregnancy will remain but 
could be substantially reduced. 
2.1. Maternal age-specific risk 
The best available estimate of the risk of an affected 
term pregnancy is obtained from combining data from 
published series of birth prevalence for individual years of 
age which were carried out before prenatal diagnosis 
became common.  Four such meta-analyses have been 
published based on eleven different maternal age specific 
birth prevalence series.  The studies differed in the 
number of series included, the method of pooling series, 
the type of regression equation and the extent to which 
the maternal age range was restricted.  As a result there 
are 19 published regression curves.  
The most widely cited curve was based on all eight 
series published at that time with a total of 4-5,000 DS and 
more than 5 million unaffected births [2].  For each year of 
age data were pooled by taking the average birth 
prevalence rate across the series weighted by the number 
of births.  Another curve used the same series but birth 
prevalence numerators and denominators were pooled; 
also a separate curve was derived pooling just the two 
series which the authors regar d e d  t o  b e  m o s t  c o m p l e t e  
[17].  A third study extended these two series by adding 
more recent data, and pooled them with two newer series 
[18].  The last study included nine series, six of those used 
in [2], the four in [18] and a further new series [19].   
Pooling made use of a weighting factor which estimates 
the proportional under-ascertainment in each series, and 
is derived simultaneously with the curve parameters.   
There is little practical difference between the 19 
curves over the 15-44 year age range but emerges later.  
By age 50 the risks range from 1 in 5 to 1 in 18.  Recently 
another curve has been published based on 11,000 cases 
from the National Down Syndrome Cytogenetic Register 
for England and Wales [20].   This curve differs 
significantly from the curve in [2] for older women: higher 
at age 36-41 and considerably lower after 45.  However, 
unlike the other series, 45% of the cases were diagnosed 
prenatally and 82% of these ended in termination of 
pregnancy, potentially introducing a strong bias [21].   
Birth prevalence was estimated by assuming an intra-
uterine survival rate following prenatal diagnosis derived 
from studies of older women [22].  This rate may not be 
applicable to women having prenatal diagnosis because of 
antenatal screening since they are younger, and extreme 
levels of the various screening markers are associated 
with non-viability. 
2.2. Impact of the strategy  
Knowing their increased DS risk an individual 
couple may decide to avoid pregnancy at an advanced 
age.  This raises the possibility of a public health strategy 
based on routinely informing couples of their age-specific 
in a family planning context.  It is not possible to judge 
how effectiveness this might be in practice but a 
theoretical maximum can be estimated for the overall 
impact on DS birth prevalence if all families are completed 
before different ages.   
It is possible to estimate the DS birth prevalence of a 
specific country, in the absence of prenatal diagnosis, by 
the average age-specific risk of an affected term 
pregnancy weighted by the proportion of maternities at 
each completed year of age.  Applying one of the above 
risk curves [2] to maternal age distribution for England 
and Wales in 2002 [23] yields prevalence of 1.89 per 1,000 
births. If all families had been completed by age 30 and 
assuming that the age distribution was unaltered before 
that age the prevalence would only have been 0.80 per 
1,000, a 58% reduction.  Completion by age 25 would 
reduce prevalence to 0.68 per 1000 or 64%.     
Whilst this is purely theoretical it should be noted 
that the maternal age distribution is not uniform over 
time.  In England and Wales there has been a steady 
increase in the average maternal age in recent years.  For 
example, in 1988 it was 26.7 years compared with 2002 
when it was 28.8 years [24]. Consequently, the estimated 
DS birth prevalence in 1988 was 1.31 per 1,000, 30% lower 
than in 2002. 
2.3. Paternal age-specific risk 
Maternal and paternal ages are highly correlated 
with relatively little variability in the age difference 
between the two parents.  But if the male partner is 
substantially older than the mother the couple might 
consider completing their family while he is relatively 
young.  However, there is little evidence for a large 
paternal age risk independent of the maternal age risk.    
Given the correlation between ages an extremely 
l a r g e  n u m b e r  o f  a f f e c t e d  c o u p l e s  w o u l d  h a v e  t o  b e  
investigated in order to discern any independent paternal 
age effect.  Consequently, some small studies have 
reported an effect [25-26], but many others found none.   
The most compelling evidence for an effect comes 
from a study of French donor insemination centres, where 
there is a large age difference between donors and 
recipients [27].  A statistically significant effect of donor 
age was reported, but it was much smaller than the 
maternal age effect.   
3.  Pre-implantation genetic diagnosis 
Assisted reproduction technologies developed to 
combat infertility are increasingly being used in couples at 
high risk of certain genetic inherited disorders.  These 
couples can now be reasonably assured of a normal 
pregnancy by using a donor egg or sperm depending on 
which partner carries the risk.  Moreover, the technique of 
PGD can be applied in order to achieve a normal 
pregnancy with the couples own gametes.   
Initially the principle indication for PGD was an 
inherited single gene or X-liked disorder or for the small 
number of couples carrying a balance translocation.  Now 
it is carried out for the more common situation where the 
couple are at high a priori risk because of a having had a 
previous child with standard trisomy or in some services 
were they are simply at advanced reproductive age.   
The selection of normal embryos following PGD 
performed on blastomeres is not perfect and there is a 
residual risk of aneuploidy.  An alternative PGD method 
based on fluorescence in-situ hybridisation (FISH) 
analysis of the first and second polar bodies has been 
developed to overcome this.   
3.1. DS recurrence risk  
When there is a parental structural chromosome 
rearrangement the recurrence risk can be quite high, 
depending on the specific genotype.  For the most 
common genotype, a Robertsonian balanced translocation, 
if the mother is the carrier the recurrence risk is great 
enough to dwarf the age-specific risk at most ages, whilst 
in male carriers the risk is not high.  For example, among 
185 amniocenteses in carrier women 15% of fetuses had a Int. J. Med. Sci. 2005 2  95
translocation, whilst all 70 amniotic fluid samples had a 
normal karyotype when the man was a carrier [28]. 
Translocation carriers are usually identified as a 
result of karyotyping affected infants or in prenatal 
diagnosis.  The finding of a structural rearrangement will 
lead to the parents and other close relatives being 
karyotyped.  Another common situation is for a parental 
translocation to be found when couples with recurrent 
early miscarriages are karyotyped. 
If a woman has had a previous pregnancy with 
Down’s syndrome and the additional chromosome 21 was 
non-inherited there is still an increased risk of recurrence.  
The increase has been estimated at three points in 
pregnancy.  In an unpublished study of more than 2,500 
women who had first trimester invasive prenatal 
diagnosis because of a previous affected pregnancy, the 
Down’s syndrome incidence was 0.75% higher than that 
expected from the maternal-age distribution (Kypros 
Nicolaides, personal communication).  Similarly, a meta-
analysis of four second trimester amniocentesis series 
totalling 4,953 pregnancies found an excess of 0.54% [3].  
A meta-analysis of 433 livebirths had 5 recurrences, an 
excess risk of 0.52% [29].  The weighted average of these 
rates, allowing for fetal losses is 0.77% in the first 
trimester, 0.54% in the second and 0.42% at term.   
Examination of the data suggests that the excess is similar 
at different ages so the excess can be added to the age-
specific risk expressed as a probability.  The recurrence 
risk is relatively large for young women but by the age of 
about 40 it is not materially different from the risk in 
women without a family history.  
Among women with non-inherited DS many are 
likely to have recurrence due to chance alone and a subset 
with a genetic cause.  Mosaicism may be involved but is 
rarely seen in peripheral blood [30] even using molecular 
techniques [31].  Another possibility is inheritance of a 
cytoplasmic risk factor which is supported by data from 
families with either two DS cases or one DS and another 
aneuploidy in which there were different reproductive 
partners in the parental or grand-parental generation.   
There are 14 case reports of this nature in the literature 
and in all but one, from a highly inbred population, 
recurrence was on the maternal side [3].  
3.2. Experience with the technique 
Studies of pre-implantation embryos show that most 
have an aneuploid, mosaic or chaotic karyotype.  And the 
frequency of euploidy is particularly uncommon when the 
parents have a balanced translocation, previous 
aneuploidy or advanced age.  Nevertheless PGD can help 
to achieve a normal pregnancy in such couples who are at 
high a priori risk.   
In a series of 49 couples with a balanced 
translocation treated in one centre, 1,408 oocytes were 
obtained and 938 were fertilised, of which one-fifth were 
normal or had a balanced translocation [32].  Following 64 
treatment cycles some 20 pregnancies were established 
and 14 of the couples had a normal delivery.  Among 48 
women who had a previous pregnancy with non-
inherited aneuploidy there were 118 normal embryos 
among 378 examined [33].  In 41 treatment cycles 21 
pregnancies were established.    In one centre carrying out 
PGD for advanced reproductive age, using the polar body 
method 8,382 oocytes were obtained in 1,297 cycles from 
patients of advanced maternal age [34].  FISH was 
informative in 80% and nearly half were found to be 
euploid.  Embryo transfer in 1,100 treatment cycles 
resulted in 241 clinical pregnancies and 176 normal 
deliveries. 
4.  Folic acid supplementation 
There is a growing body of evidence suggesting that 
DS might be linked to abnormal folate and methyl 
metabolism.  This can lead to DNA hypo-methylation, 
instability, abnormal segregation and aneuploidy [35-36].  
Whilst the aetiological implications of the available data 
are uncertain, a case can now be made for performing a 
clinical trial to assess the possibility of primary prevention 
of DS by dietary supplementation.  Meanwhile the 
strategy of folic acid supplementation designed to prevent 
fetal neural tube defects (NTDs) might incidentally reduce 
the DS risk provided a high enough dose is used. 
4.1. Evidence of a link 
A study of 41 mothers of DS infants found a 
statistically significant increase in plasma homocystine 
(Hcy) compared to controls [8].  Hcy is a sensitive marker 
of folate status that is inversely correlated with levels of 
folate in plasma, and both folate and methyl folate in red 
blood cells [37-38].  The study also found reduced 
methionine in cases and an increased ratio of plasma Hcy 
to methionine and increased sensitivity to methotrexate 
cytotoxicity - an indicator of functional folate metabolism.   
There have been six studies of MTHFR 
polymorphisms and two studies of MTRR [8-13].  Some 
have reported increased frequency of the MTHFR 
677C→T and MTRR 66A→G mutant alleles, overall or in 
subgroups, but the results are not consistent.  Both 
MTHFR and MTRR mutations could be critical for DNA 
methylation.  MTHFR catalyses the conversion of 5,10-
methylene-tetrahydrofolate (THF) to 5-methyl-THF, the 
methyl donor in the remethylation of homocysteine to 
methionine by methionine synthase, which in turn is 
maintained in its active form by MTRR. 
The concept of a link with abnormal folate 
metabolism was given a boost by a recent study of 493 
families who were at high NTD risk, 445 with a history of 
NTD and 48 with isolated hydrocephalus, there were 11 
DS cases among 1,492 at risk pregnancies, compared with 
1.87 expected on the basis of maternal age, a highly 
statistically significant excess [14]. In the same study a 
second series of 516 families at high risk of DS there were 
7 NTD pregnancies among 1,847 at risk, compared with 
1.37 expected.   
But a network of congenital malformation registries 
in Latin America have failed to confirm these results [39].  
When affected pregnancies are registered an interviewer 
takes a clinical history from the mother, including about 
previous affected pregnancies.  The study identified five 
cases of Down’s syndrome occurring among 5404 
pregnancies previous to NTD or hydrocephalus, and 12 
cases of NTD or hydrocephalus occurred among 8066 
pregnancies previous to DS.  Neither of these figures was 
excessive as the expected values based on prevalence 
within the network was 5.1 and 17.2 respectively. One 
possible explanation is the underreporting of familial 
cases.  Registries are not well suited to this kind of 
investigation as they concentrate on individual cases 
rather than families and are generally poor at record 
linkage.  It is also possible that the effect observed in Israel 
and Ukraine is not present in Latin America where the 
genetic basis of NTDs may differ.   Int. J. Med. Sci. 2005 2  96
4.2. Supplementation 
Dietary intervention studies show that genomic 
instability is minimised when the plasma folate level 
exceeds about 34 nmol/l and the Hcy level is less than 7.5 
µmol/l [35].  These levels can only be achieved when folic 
acid intake is above 5mg per day.  Currently, the 
recommended daily dose for the prevention of NTDs in 
women with no previous affected pregnancies is 0.4mg 
but it has now been estimated that a much higher intake 
would be required to have a substantial benefit and the 
authors recommend 5mg [40].  The higher dose would 
increase serum folate levels 5-20 fold, depending on the 
background level.  A meta-analysis of cardiac prevention 
trials found an average Hcy reduction of 25% for an intake 
of 2.2mg per day on average [41].  In another publication, 
five women with folate deficiencies who were given 10mg 
per day for two months there was, on average, a 53% 
reduction in plasma Hcy [37].  
Reductions in NTD prevalence over time and within 
non-randomised supplementation trials cannot be 
attributed to folic acid alone [40].  Another possibility is a 
defect in the metabolism or transport of vitamin B12 
(cobalamin) an essential cofactor in the folate-homocystine 
cycle.  Low maternal levels are associated with increased 
NTD risk, independent  of folate status [42] and the 
relative risk of NTD conferred by the MTRR G/G 
genotype is greater in mothers with levels in the lowest 
quartile [43].  Vitamin B12  deficiency is also associated 
with genomic instability and when plasma levels fall 
below 300pmol/l [35].  Adjuvant supplementation with 
cobalamin enhances the reduction of Hcy compared to 
folic acid alone [35,41]. 
An association has been found between spontaneous 
abortions and a polymorphism, Pro259Arg, in the gene for 
transcobalimin, a protein that binds cobalamin and 
transports it to peripheral tissue [44].  This may be 
regarded as further evidence of an NTD-DS link since a 
large proportion of abortuses have these defects.  Low 
maternal blood folate levels are also associated with 
miscarriage [45].   
A large trial of folic acid and possibly cobalamin 
supplementation would be needed before DS prevention 
can be established and a public health policy on the matter 
is justified.  Meanwhile, the existing programs designed to 
prevent NTDs might incidentally prevent DS, although 
the higher 5mg dose would probably be needed. 
5.  Aetiological research  
The risk factors highlighted by epidemiological 
study, particularly the maternal age effect, have given rise 
to a number of aetiological hypotheses.  More focused 
research is urgently needed to test them in greater depth 
than in the past and in particular some recent aetiological 
clues should be built on.   
5.1 Production line hypothesis 
Oocytes formed in late fetal life have fewer 
chiasmata and more univalents, rendering them 
susceptible to non-disjunction.  The production line 
hypothesis proposes that the order in which oocytes 
ovulate within a woman’s reproductive life is determined 
by the order in which they were produced in utero [46].  It 
has been tested in animal models using various 
experimental methods with no clear and consistent 
supportive evidence [47-50].   
5.2  Ageing oocyte hypotheses 
The cause of DS has been sought in disturbances 
during stages of oogenesis, including the period of meiotic 
arrest of the oocyte [51].  This has generated several 
hypotheses. 
One possibility is that the frequency of persistent 
nucleoli in MI prophase is increased in older women due 
to the long dictyate stage.  This would lead to errors in 
meiotic segregation of acrocentric chromosomes where 
nucleolar fusion holds together the short arms [52].   
However, this hypothesis and its variants could not 
explain trisomy among non-acrocentric chromosomes 
[53]. 
Over the long meiotic prophase, damage of spindle 
components whether by intrinsic factors or by the 
accumulation of environmental insults.  For example, 
irradiation and heavy metal ions could affect oocytes 
through intracellular free radical production or oxidative 
effects.  Radio-sensitivity of oocytes in the dictyate stage 
increases with advancing maternal age [54].  Not all 
chromosomes have equal sensitivity with chromosomes 
21 and X being more susceptible to abnormal segregation 
[55]. 
5.3 Relaxed selection hypothesis 
The propensity for affected fetuses to miscarry might 
decrease with advancing maternal age – relaxed selection 
[56].  If this were true the mean maternal age would be 
lower in trisomy 21 miscarriages than births.  Since 
normal miscarriage increases with age [57] the hypothesis 
can best be tested by comparing the maternal age 
difference between miscarriages and births for DS with 
that for normal pregnancies.  In the two large New York 
and Hawaii studies which karyotyped large numbers of 
miscarriages the difference for normal pregnancies was 
1.0 years [58] compared with 1.2-1.8 years in New York 
and 0.3 years in Hawaii [59], an inconsistent result.   
Moreover, the results of assisted reproduction using 
donor oocytes from young women in older recipients [51] 
indicate that it is the quality of the donated oocyte rather 
than the recipients’ ability to select against abnormal 
embryos that determines a successful outcome.   
Furthermore, if there is relaxed selection against DS the 
mean maternal age would be increased in Robertsonian 
translocation cases as well as non-disjunction cases, and it 
is not [1].   
Even if relaxed selection did contribute to the 
maternal age effect it could not account for all of it since 
the incidence of trisomy 21 in miscarriages also increases 
with maternal age [58]. 
5.4 Premature reproductive ageing hypothesis 
Physiological ageing of the female reproductive 
system may be more important than chronological age per 
se; for example, depletion of the oocyte pool by 
accelerated atresia would lead to increased risk of trisomy 
[60].  In this context it is suggestive that the exponential 
decline in the number of available follicles after age 30 [61] 
mirrors the exponential rise in DS risk.   
Experiments with inbred CBA mice, which have a 
small number of oocytes that are completely depleted by 
the time ovulation ceases, support this concept.  Unilateral 
oophorectomy caused increased ovulation in the contra-
lateral ovary, an early menopause and increased 
aneuploidy risk at all ages [62].  Int. J. Med. Sci. 2005 2  97
Two human studies have reported reduced 
menopausal age in association with trisomy: in the first 
menopause was on average 10.2 years after a DS birth 
compared with 12.8 years for controls [63]; in the second 
the mean age of menopause among women with trisomic 
miscarriages was 1.0 years earlier than women with 
normal pregnancies [64]. Unilateral oophorectomy is 
likely to bring forward the age of menopause, and surgical 
removal or congenital absence of one ovary is associated 
w i t h  a  9 - f o l d  i n c r e a s e  i n  D S  r i s k  [ 6 5 ] .   W o m e n  w i t h  
Turner’s syndrome have extremely premature menopause 
and there is a very large DS risk in their pregnancies: 1.8% 
(4/221) from reports in the literature [66-67]. 
The level of serum follicle stimulating hormone is an 
indicator of impending ovarian failure.  Elevated levels 
have been reported in women with a previous DS 
pregnancy [68], and in women having early abortions for 
social reasons where karyotyping revealed fetal 
aneuploidy [69]. 
5.5 Compromised microcirculation hypothesis 
This hypothesis proposes that non-disjunction arises 
from a cascading events [70].  The suggested sequence is 
hormonal imbalance, sub-optimal micro-vasculature 
around the ovarian follicle, reduced blood flow, increased 
carbon dioxide and lactic acid inside the follicle, decreased 
pH in the oocyte, reduced mitotic spindle size, spindle 
displacement and non-disjunction.   
Whilst animal experiments do support the possibility 
that abnormal pH would lead to non-disjunction [71], two 
events in the sequence are controversial.  Firstly, the 
proponents use the J-shape of the maternal age risk curve 
as evidence for the effect of hormonal imbalance around 
the time of menarche and approaching the menopause.   
However, none of the meta-analyses cited above 
demonstrate any relatively high DS risk in very young 
women. Secondly, the purported connection between 
compromised micro-circulation and reduced pH, is the 
fact that the ovarian follicle has no internal circulation.   
But both oocytes and spermatocytes are isolated from 
direct contact with blood and it is known that the ovary is 
the most highly vascularized organ [72]. 
5.6 Delayed fertilisation and sperm ageing hypotheses 
The secondary oocyte remains in MII metaphase in 
the Fallopian tube until it is fertilised.  It has been 
proposed that ageing or over-ripeness of these cells could 
lead to a higher incidence of spindle defects and so 
increase the chance of non-disjunction.  This hypothesis 
might explain the maternal age effect, since there is 
presumed to be a decreased frequency of coitus in older 
women [73].  Such behaviour would reduce the chance of 
fertilisation before the ovum became over-ripe. 
There is epidemiological evidence which indicates 
that infrequent coitus may be a DS risk factor (see [29]).  
Some animal experiments show that chromosomal errors 
increase with delayed fertilisation, although it is difficult 
to distinguish this from the maternal age effect [74], and 
some animal experiments do not support the hypothesis; 
for a review see [75].  
It has also been proposed that sperm ageing, for 
example as a result of infrequent coitus, could be 
involved.  One possible mechanism is that chromosomally 
abnormal sperm are immature and have a competitive 
disadvantage over normal sperm, but a delay in utilisation 
would allow them to mature  and there is some animal 
evidence for this [75]. 
5.7 Mitochondrial (mt) DNA mutation hypothesis 
This proposal is that mtDNA mutations lead to a 
decline in ATP level and increased production of free-
radicals, which could affect division spindle and 
chromosome segregation, accelerate telomere shortening, 
alter recombination and cause non-disjunction of 
chromosomes [76].   
There are many features of mtDNA which are 
remarkably consistent with the epidemiology and 
molecular genetics of the disorder.  The mtDNA is almost 
entirely of maternal origin, mtDNA mutations in oocytes 
increase with age [77] and the mutations can be inherited.  
There are also mtDNA mutations involved in Alzheimer’s 
disease, diabetes and hypothyroidism, disorders which 
are relatively frequent in affected families. 
In a mouse model, it has been shown that mtDNA 
mutations can modulate the expression of an inheritable 
MI error in oocytes [78].  In humans, the excess of 
maternal over paternal remarriages in families with 
aneuploidy recurrence to different partners, is consistent 
with a cytoplasmic risk factor [3].  There is increased free-
radical activity in mothers which could be either a cause 
or result of mtDNA mutations [79].  The complete mtDNA 
was sequenced in a peripheral blood sample from the 
mother of a DS child who was the originator of the 
additional chromosome 21 [76].  There were four point 
mutations not previously described, each of which is 
likely to disrupt mitochondrial function.  Similarly, three 
DS individuals were sequenced and a high incidence of 
potentially disruptive base changes were found [80].  
5.8 Way forward 
Now that the vast majority of DS birth can be 
prevented through antenatal screening a refocusing of 
research is called for with more effort placed on aetiology.  
Furthermore, the research effort needs to be more multi-
disciplinary than in the past.  Although maternal age and 
family history are the main epidemiological variables 
there are many smaller but well established factors, such 
as a very reduced DS risk in twins, which may provide 
aetiological clues [4].  Those working at the molecular 
level, with animal models or in clinical chemistry need to 
be aware of these effects.  Similarly, observations in the 
laboratory should be made known to epidemiologists so 
that comparable human evidence can be sought.  With a 
concerted sustained effort large scale primary prevention 
may be realised in the near future.  
6.  Conclusions 
From the beginning of their reproductive life women 
have the option to reduce the DS risk by completing their 
family by age 30.  On a population level this strategy 
could more than halve the birth prevalence of this 
disorder.   
Women with a high a priori D S ri sk b ecau se o f an  
inherited translocation or a previous pregnancy with a 
non-inherited form of DS should have access to PGD.  The 
effectiveness of this technique is limited by the availability 
of normal embryos in such families but reasonably high 
pregnancy rates are achievable with an extremely low risk 
of a DS birth.  However, only about 1% of DS pregnancies 
are in women with a family history of the disorder so the 
impact of this activity on birth prevalence is minimal.  In 
some localities women of advanced reproductive age also Int. J. Med. Sci. 2005 2  98
have access to PGD which could potentially have a much 
greater impact on prevalence.   
Biochemical, molecular and epidemiological 
evidence suggests a link between DS and a defect in folate 
and methyl metabolism. This is not sufficient to justify an 
active preventative strategy of folic acid supplementation 
without performing a large clinical trial.  However, 
current supplementation policies designed to prevent 
NTDs may incidentally prevent DS, provided a 
sufficiently high dose of folic acid and possibly cobalamin 
is used.   
Further progress in the primary prevention of DS is 
hampered by limited knowledge of the cause of this 
disorder.  There is an urgent need to refocus research in 
that direction. 
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